| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate |
2004-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfaa406fda6835d95a180adaa60ee46d |
| publicationDate |
2006-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006040854-A1 |
| titleOfInvention |
Prostate hyperplasia therapy |
| abstract |
The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009142336-A1 |
| priorityDate |
2004-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |